Back to Search
Start Over
Phase I Clinical Study of the Dietary Supplement, Agaricus blazei Murill, in Cancer Patients in Remission.
- Source :
-
Evidence-based Complementary & Alternative Medicine (eCAM) . Jan2011, Vol. 8 Issue 1, p1-9. 9p. 2 Diagrams, 4 Charts. - Publication Year :
- 2011
-
Abstract
- Although many cancer patients use complementary and alternative medicine, including Agaricus blazei Murill (ABM), safety is not yet well understood. Cancer survivors took 1.8, 3.6, or 5.4 g ABM granulated powder (Kyowa Wellness Co., Ltd., Tokyo, Japan) per day orally for 6 months. Adverse events were defined by subjective/objective symptoms and laboratory data according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (NCI-CTCAE v3.0). Seventy-eight patients were assessed for safety of ABM (30/24/24 subjects at 1/2/3 packs per day, resp.). Adverse events were observed in 9 patients (12%). Most were digestive in nature such as nausea and diarrhea, and one patient developed a liver dysfunction-related food allergy, drug lymphocyte product. However, none of these adverse events occurred in a dose-dependent manner. This study shows that ABMdoes not cause problems in most patients within laboratory parameters at the dosages tested over 6 months. This trial supports previous evidence that the ABM product is generally safe, excluding possible allergic reaction. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 1741427X
- Volume :
- 8
- Issue :
- 1
- Database :
- Academic Search Index
- Journal :
- Evidence-based Complementary & Alternative Medicine (eCAM)
- Publication Type :
- Academic Journal
- Accession number :
- 82074776
- Full Text :
- https://doi.org/10.1155/2011/192381